Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MYC RNA refers to the messenger RNA (mRNA) transcript of the MYC proto-oncogene, a master regulator gene that encodes a transcription factor involved in cell proliferation, growth, apoptosis, and metabolism. The MYC family includes c-myc (MYC), l-myc (MYCL), and n-myc (MYCN). In cancer biology, overexpression or dysregulation of MYC is implicated in many malignancies including Burkitt lymphoma and various solid tumors. Because the Myc protein has been considered "undruggable" by traditional small molecule approaches due to its lack of suitable binding pockets[1][5][9], recent drug discovery efforts have focused on targeting the MYC mRNA itself using modalities such as small interfering RNAs (siRNAs), antisense oligonucleotides, or small molecules that bind to structured regions of the mRNA to inhibit translation or promote degradation[5][6][8][9]. These approaches aim to reduce production of Myc protein and thereby suppress tumor growth.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on MYC RNA.